Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab is effective for standard-risk hematological malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

YNYuhei NakamuraMKMachiko KusudaÞHÞorvarður R. Hálfdánarson

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates improved outcomes of haploidentical HSCT in standard-risk hematological malignancies, highlighting low relapse rates with specific interventions.

Key Points

  • To evaluate the effectiveness of haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab in patients with hematological malignancies.
  • Conducted a retrospective study of patients who underwent haploidentical HSCT using low-dose alemtuzumab from 2015 to 2024.
  • Utilized anti-CD52 antibody alemtuzumab and specific GVHD prophylaxis regimes based on disease risk.
  • Analyzed clinical outcomes like overall survival, disease-free survival, and relapse rates.
  • Of the 75 patients analyzed, those with standard-risk disease showed higher overall survival rates at 1 and 3 years compared to high-risk patients.
  • The study reported a significant low relapse rate in patients classified under standard-risk disease.
  • A tendency for lower incidence of acute and chronic graft-versus-host disease was observed despite reduced doses of methotrexate.

Cite This Study

Nakamura et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db9bhttps://doi.org/10.1182/blood-2025-5995
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  2. 2T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  3. 3Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party2026 · 1 citations
  4. 4Results of allogeneic hematopoietic stem cell transplantation from a genoidentical sibling after high-dose treosulfan-based conditioning in children with intermediate-risk acute myeloid leukemia in first clinical and hematological remission2025
  5. 5Real-World Challenges of Haplo-Identical Hematopoietic Stem Cell Transplant in a Developing Country: A Single Center Experience2024 · 1 citations